Asceneuron Appoints Prominent Healthcare Leader Catherine Moukheibir to its Board of Directors

Lausanne, SWITZERLAND and San Francisco, CA, USA, 16 July 2021 – Asceneuron SA, a clinical stage company dedicated to targeting the root cause of neurodegenerative diseases, announced today the appointment of Catherine Moukheibir to its Board of Directors.
Catherine is a highly respected healthcare executive with extensive experience over the last 30 years of leadership in finance, capital markets and life sciences. She has previously worked as a Chairman, Non-Executive Director and Chief Executive Officer in the biotech and pharmaceutical sectors, successfully raising private and public capital as well as overseeing several major licensing deals and acquisitions.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH